

The impact of lithium on prooxidant-antioxidant balance in human plasma *in vitro* and in neuronal cell lines



Oliwia Gawlik, MD¹

Wojciech Mielicki, PhD²

Jolanta Rabe -Jabłońska MD, PhD¹

¹Department of Affective and Psychotic Disorders

²Department of Pharmaceutical Biochemistry

Medical University of Łódź



Lithium

Medical use

- ✓ first-line treatment of manic episodes;
- ✓ treatment option for bipolar depressive episodes;
- ✓ augmentation therapy of medication-resistant depression or schizophrenia.

Mechanism of action

- ✓ ion transport,
- ✓ neurotransmitter signaling,
- ✓ signal transduction (phosphoinositide cycle, adenylyl cyclase G proteins, protein kinases),
- ✓ gene expression,
- ✓ neuroplasticity and cytoskeletal remodeling,
- ✓ **neuroprotection and antioxidation**


Introduction



Oxidative stress

„disturbance in prooxidant-antioxidant balance in favour of the former, leading to potential damage” (Sies, 1991)

- patients with BD have increased lipid peroxidation (acute manic and depressive episodes, remission);
- a potential role of glutamate-induced oxidative stress in BD?
- excessive generation of ROS triggered by mitochondrial dysfunction in BD?





Methods

Human plasma *in vitro*:

- plasma samples from healthy volunteers;
- plasma incubation (24h, 37 °C):
 - without the drug;
 - with lithium alone (0,67 or 1,0mmol/l);
 - with lithium and haloperidol (10ng/ml)

Lipids peroxidation (LP) measurement by the concentration of thiobarbituric acid reactive substances (TBARS) (Rice-Evans).




Determination of **total antioxidant capacity (TAC)** with ABTS radical cation (ABTS⁺) decolorization assay (Re).

Neuroblastoma

- SH-SY5Y cells were used. Two kinds of experiments were performed:
- ✓ Cells were treated with various concentrations of lithium (0,67mmol/l and 1,00 mmol/l) and haloperidol (10ng/ml) for 48h;
 - ✓ Cells were pretreated with various concentrations of lithium (0,67mmol/l and 1,00 mmol/l) and haloperidol (10ng/ml) for 24h and then treated with hydrogen peroxide (150μM) for another 24h;
 - ✓ Lipid peroxidation and cell viability were measured.

Oxidative stress level was assessed by **lipid peroxidation** measurement (Rice-Evans method).



Cell viability was measured by MTT assay - colorimetric assay for measuring the activity of enzymes that reduce MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to purple formazan dyes.

Statistical analysis

The scientific statistic software Statistica 10.0 was employed.


Results

We observed:


- no influence of lithium on lipid peroxidation (fig. 1) nor TAC (fig. 2) in human plasma *in vitro*;
- increase in lipid peroxidation in samples with combination of lithium and haloperidol in human plasma *in vitro* (fig. 1); no differences in TAC between the samples;
- no influence of lithium, haloperidol and combination of lithium and haloperidol on lipid peroxidation in SH-SY5Y neuroblastoma cells (fig. 3);
- no influence of pretreatment with lithium, haloperidol and combination of lithium and haloperidol on lipid peroxidation in SH-SY5Y neuroblastoma cells treated with hydrogen peroxide (fig. 4);
- higher viability in SH-SY5Y neuroblastoma cells cultures incubated with lithium (fig. 5); no influence of haloperidol and combination of lithium and haloperidol on cells viability.

Human plasma *in vitro*

Lipid peroxidation




Total antioxidant capacity




Neuroblastoma SH-SY5Y


LP - neutral environment



LP - prooxidative environment



Cells viability



Conclusions

- lithium in concentrations used in psychiatry does not influence oxidative stress parameters in *in vitro* conditions (human plasma, neuroblastoma cells) in a short-period observation (24 or 48h) what is consistent with some of the previous studies;
- lithium in combination with haloperidol increases lipid peroxidation compared to control, lithium or haloperidol alone, thus one should be careful prescribing those drugs together; the mechanism may be responsible for some side effects (e.g. neurotoxicity) of the combination;
- inconsistency of research in the field causes necessity for further studies to assess lithium impact on oxidative stress parameters: in *in vivo* conditions, in a long-period observation, in neutral and prooxidative environment (patients with bipolar disorder);
- further studies may provide additional data regarding the possible involvement of oxidative stress in the pathophysiology of BD and in the therapeutic effects of lithium.

Literature

- Aliyazicioglu R, Kural B, Colak M, Karahan SC, Ayvaz S, Deger O. Treatment with lithium, alone or in combination with olanzapine, relieves oxidative stress but increases atherogenic lipids in bipolar disorder. *Tohoku J Exp Med* 2007; 213: 79-87.
- Machado-Vieira R, Andreasz AC, Viale CI, Zanatto V, Cereser Jr V, da Silva Vargas R i wsp. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. *Neurosci Lett* 2007; 421: 33-36.
- Vasconcelos APS, Nieto FB, Crema LM, Diehl LA, Almeida LM, Prediger ME i wsp. Chronic Lithium Treatment has Antioxidant Properties but does not Prevent Oxidative Damage Induced by Chronic Variate Stress. *Neurochem Res* 2006; 31: 1141-1151.
- Oktem F, Ozguner F, Sulak O, Olgar S, Akturk O, Yilmaz HR i wsp. Lithium-induced renal toxicity in rats: protection by a novel antioxidant caffeic acid phenethyl ester. *Mol Cell Biochem* 2005; 277: 109-115.

Acknowledgments

This work was supported by Medical University of Lodz, Grant no. 502-11-756 and the Polish Ministry of Science and Higher Education, Grant no. N N402 456138.

Contact information

Oliwia Gawlik, M.D.;
e-mail address: oliwia.gawlik@umed.lodz.pl;
Department of Affective and Psychotic Disorders,
Medical University of Lodz;
92-216 Lodz, Czechoslowacka 8/10, Poland